We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Insulet (PODD) Shows Strength: Stock Adds 7.1% in Session
Insulet Corporation (PODD - Free Report) was a big mover last session, as its shares rose over 7% on the day. The move came on the back of revenue growth and raised 2017 guidance in second-quarter 2017 results. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range $49.49 to $53.52 in the past one-month time frame.
Over the last 30 days, the company witnessed one negative estimate revision. However, the Zacks Consensus Estimate remained unchanged over the same time frame. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Insulet currently carries a Zacks Rank #3 (Hold).
Insulet Corporation Price
Insulet Corporation Price | Insulet Corporation Quote
A better-ranked stock in the Medical – Products space is INSYS Therapeutics, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PODD going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>